Quantcast
Last updated on April 18, 2014 at 15:51 EDT

Latest Complement component 3 Stories

2012-05-14 22:17:48

Pursuing a relatively untapped route for regulating the immune system, an international team of researchers has designed and conducted initial tests on molecules that have the potential to treat diseases involving inflammation, such as asthma, rheumatoid arthritis, stroke and sepsis. The team started by creating a three-dimensional map of a protein structure called the C3a receptor, which sits on the surface of human cells and plays a critical role in regulating a branch of the immune...

2011-02-04 12:33:00

This week, the highly-respected US Academy of Sciences journal (PNAS) published an article describing how the first line of defence of the human immune system distinguishes between microbes and the body's own structures. The basis of this recognition mechanism has been unclear since the key protein components were discovered over 30 years ago "“ and has now finally been cracked by a collaboration between high-level research groups at the University of Helsinki, Finland. When a microbe...

4c03017e25e7bd24aab1a817c85f825d1
2009-06-17 14:40:00

How molecules of the oldest branch of the human immune system have interconnected has remained a mystery. Now, two new structures, both involving a central component of an enzyme important to the complement system of the immune response, reveal how this system fights invading microbes while avoiding problems of the body attacking itself.The structures may pave the way to more efficient therapeutics for such complement-mediated diseases as age-related macular degeneration, rheumatoid...

2008-07-28 09:00:31

SAN FRANCISCO, July 28 /PRNewswire/ -- InCode BioPharmaceutics, Inc. today announced favorable results of its preclinical primate toxicity study demonstrating no adverse events and reduction of key markers of potency for its lead drug candidate, rC3-1. In the study, escalating doses of rC3-1 were delivered directly to the pulmonary artery of non-human primates. The lung is considered to be the target organ for potential toxicity. All doses recorded no clinically significant changes in...

2008-07-23 12:00:26

SAN FRANCISCO, July 23 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug candidate rC3-1 for the treatment of the rare chronic blood disorder paroxysmal nocturnal hemoglobinuria (PNH). The complete results will be presented at the XXII International Complement Workshop in Basel, Switzerland, September 28, 2008. The only treatment currently available for PNH patients is...